Midatech secures exclusive position to exploit magnetic noble metal nanoparticles through new IP licenses
Technology has potential applications in bacterial infection and cancer
Midatech's biocompatible nanoparticles have a range of unique characteristics that make them ideal for applications such as targeted drug delivery and diagnostic imaging. Their innate magnetic properties allow for localised drug release or cell apoptosis upon application of a radiofrequency electromagnetic field. Less than 10nm in diameter, these nanoparticles contain a noble metal (e.g. gold) core, and at this nano-scale exhibit ferromagnetic-like behaviour. Exposure to an alternating magnetic field causes the nanoparticle core to absorb the field energy, which is then released as heat or chemical energy. The nanoparticles can be targeted to specific tissues, cells or intracellular locations by molecular area coding.
"This radiofrequency heating technology, when applied to our unique nanoparticle design, has exceptionally wide-ranging applications, a particular example being the use of localised heat to kill cancerous cells and drug resistant bacteria (MRSA). The licensing of these patents has strengthened our extensive IP portfolio and further increases the scope of our technology development with regards to therapeutic nanoparticles", commented Professor Tom Rademacher, Chairman of Midatech Group.
Further proof of concept on the development of localised heating technology will be carried out at the CSIC, Seville, under R & D Agreement, under the direction of Professor Asunción Fernández, Head of the Nanostructured Materials group at the Materials Science Institute.
Most read news
Topics
Organizations
Other news from the department research and development
These products might interest you
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
DynaPro Plate Reader III by Wyatt Technology
Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)
Efficiently characterize your sample quality and stability from lead discovery to quality control
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.